Dr. Reddy's Laboratories Surpasses Q3 Expectations, Stock Sees Gains Amidst Geographic Performance Differentiations

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Dr. Reddy's Laboratories Surpasses Q3 Expectations, Stock Sees Gains Amidst Geographic Performance Differentiations
Overview

Dr. Reddy's Laboratories announced its Q3 FY26 financial results, reporting consolidated revenue of ₹8,726.8 crore, a 4.4% increase year-over-year, and a net profit of ₹1,209.8 crore. While profit saw a 14.4% year-on-year decline, it surpassed market expectations. Growth was significantly driven by its India and emerging markets segments, compensating for a downturn in its North America business. The positive results led to an increase in the company's stock price in early trading.

Q3 Financial Performance

Dr. Reddy's Laboratories reported a consolidated net profit of ₹1,209.8 crore for the third quarter of fiscal year 2026. This figure represents a 14.4% decrease compared to the same period last year but was higher than the approximately ₹1,070 crore anticipated by analysts. Revenue from operations saw a 4.4% year-over-year rise, reaching ₹8,726.8 crore. The company's EBITDA for the quarter was ₹2,049.3 crore, with an EBITDA margin of 23.5%. Gross margins experienced a moderation, falling to 53.6% from 58.7% a year prior.

Geographic Drivers and Market Dynamics

The company's performance in the quarter was characterized by divergent trends across its key markets. India emerged as a significant growth engine, with revenues climbing by 19% year-over-year. This expansion was supported by price adjustments and the integration of the Stugeron brand acquired from Johnson & Johnson. Emerging markets also demonstrated robust performance, recording a 32% year-over-year increase in revenue, with Russia showing a notable 51% growth. In contrast, the North America segment experienced a 12% decline in revenue, primarily attributed to reduced sales of Lenalidomide. Despite the overall dip in North America, the business excluding Lenalidomide showed a marginal increase of 2.6% against a market decline of 0.3%. Europe also contributed positively with a 20% year-over-year revenue increase.

Pipeline and Future Catalysts

Looking ahead, Dr. Reddy's is focusing on key product developments. The company has received marketing authorization for Semaglutide injection in India and is targeting a launch in March 2026. Regulatory approval for Semaglutide in Canada is anticipated between February and May 2026, with a potential launch in the fourth quarter of 2026 or the first quarter of 2027. Filings for Semaglutide are planned across approximately 80 markets. The company also advanced its biosimilar pipeline with a December 2025 BLA filing for the IV formulation of Abatacept, with global launches anticipated around July 2027.

Market Performance Analysis

Following the announcement of the Q3 results, Dr. Reddy's shares saw an increase. As of Thursday, January 22, 2026, the stock was trading around ₹1,208 on the NSE, reflecting a gain of approximately 4.4% from its previous close. Brokerages have shown a more constructive stance; HSBC maintained a 'Buy' rating with a target price of ₹1,435, while CLSA upgraded the stock to 'Hold' from 'Sell', setting a target of ₹1,210. The company's market capitalization stands at approximately ₹96,583 crore, with a trailing twelve-month Price-to-Earnings (P/E) ratio in the range of 16.8 to 17.8.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.